Effect of selected catechins on doxorubicin antiproliferative efficacy and hepatotoxicity in vitro

1. R. Ng, N. Better and M. Green, Anticancer agents and cardiotoxicity, Semin. Oncol. 33 (2006) 2-14; DOI: 10.1053/j.seminoncol.2005.11.001.10.1053/j.seminoncol.2005.11.001Search in Google Scholar

2. K. Schimmel, D. Richel, R. van den Brink and H. J. Guchelaar, Cardiotoxicity of cytotoxic drugs, Cancer Treat. Rev. 30 (2004) 181-191; DOI: 10.1016/j.ctrv.2003.07.003.10.1016/j.ctrv.2003.07.003Search in Google Scholar

3. T. Simunek, M. Sterba, O. Popelova, M. Adamcová, R. Hrdina and V. Gersl, Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron, Pharmacol. Rep. 61 (2009) 154-171.Search in Google Scholar

4. S. Kalender, Y. Kalender, A. Ates, M. Yel, E. Olcay and S. Candan, Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats, Braz. J. Med. Biol. Res. 35 (2002) 1379-1387; DOI: 10.1590/s0100-879x2002001100017.10.1590/S0100-879X2002001100017Search in Google Scholar

5. Y. Kalender, M. Yel and S. Kalender, Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats - the effects of vitamin E and catechin, Toxicology 209 (2005) 39-45; DOI: 10.1016/j.tox.2004.12.003.10.1016/j.tox.2004.12.003Search in Google Scholar

6. J. H. Doroshow, Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents, Biochem. Biophys. Res. Commun. 135 (1986) 330-335; DOI: 10.1016/0006-291x(86)90981-2.10.1016/0006-291X(86)90981-2Search in Google Scholar

7. B. K. Sinha, A. G. Katki, G. Batist, K. H. Cowan and C. E. Myers, Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells, Biochem. Pharmacol. 36 (1987) 793-796; DOI: 10.1016/0006-2952(87)90164-x.10.1016/0006-2952(87)90164-XSearch in Google Scholar

8. A. L. A. Ferreira, L. S. Matsubara andB. B. Matsubara, Anthracycline-induced cardiotoxicity, Cardiovasc. Hematol. Agents Med. Chem. 6 (2008) 278-281; DOI: 10.2174/187152508785909474.10.2174/18715250878590947418855640Search in Google Scholar

9. C. Carvalho, R. X. Santos, S. Cardoso, S. Correia, P. J. Oliveira, M. S. Santos and P. I. Moreira, Doxorubicin: the good, the bad and the ugly effect, Curr. Med. Chem. 16 (2009) 3267-3285; DOI: 10.2174/092986709788803312.10.2174/09298670978880331219548866Search in Google Scholar

10. Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield and D. K. St Clair, Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues, Mol. Interv. 7 (2007) 147-156; DOI: 10.1124/mi.7.3.6.10.1124/mi.7.3.617609521Search in Google Scholar

11. A. Mohan, S. Narayanan, S. Sethuraman and U. M. Krishnan, Combinations of plant polyphenols & anti-cancer molecules: a novel treatment strategy for cancer chemotherapy, Anti-Cancer Agents Med. Chem. 13 (2013) 281-295; DOI: 10.2174/1871520611313020015.10.2174/187152061131302001522721388Search in Google Scholar

12. V. Hanušová, I. Boušová and L. Skálová, Possibilities to increase the effectiveness of doxorubicin in cancer cells killing, Drug Metab. Rev. 43 (2011) 540-557; DOI: 10.3109/03602532.2011. 609174.Search in Google Scholar

13. H. K. Biesalski and J. Frank, Antioxidants in cancer therapy: is there a rationale to recommend antioxidants during cancer therapy? Biofactors 17 (2003) 229-240; DOI: 10.1002/biof.5520170122.10.1002/biof.552017012212897444Search in Google Scholar

14. K. A. Conklin, Cancer chemotherapy and antioxidants, J. Nutr. 134 (2004) 3201S-3204S.Search in Google Scholar

15. D. Procházková, I. Boušová and N. Wilhelmová, Antioxidant and prooxidant properties of flavonoids, Fitoterapia 82 (2011) 513-523; DOI: 10.1016/j.fitote.2011.01.018.10.1016/j.fitote.2011.01.01821277359Search in Google Scholar

16. L. Patil and R. Balaraman, Effect of green tea extract on doxorubicin induced cardiovascular abnormalities: antioxidant action, Iran. J. Pharm. Res. 10 (2011) 89-96.Search in Google Scholar

17. Y. Du and H. X. Lou, Catechin and proanthocyanidin B4 from grape seeds prevent doxorubicin- -induced toxicity in cardiomyocytes, Eur. J. Pharmacol. 591 (2008) 96-101; DOI: 10.1016/j.ejphar. 2008.06.068.Search in Google Scholar

18. J. Zheng, H. C. M. Lee, M. M. bin Sattar, Y. Huang and J. S. Bian, Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury, Eur. J. Pharmacol. 652 (2011) 82-88; DOI: 10.1016/j.ejphar.2010.10.082.10.1016/j.ejphar.2010.10.08221114975Search in Google Scholar

19. R. H. Mohamed, R. A. Karam and M. G. Amer, Epicatechin attenuates doxorubicin-induced brain toxicity: critical role of TNF-alpha, iNOS and NF-kappa B, Brain Res. Bull. 86 (2011) 22-28; DOI: 10.1016/j.brainresbull.2011.07.001.10.1016/j.brainresbull.2011.07.00121763406Search in Google Scholar

20. K. Sato, K. Sueoka, R. Tanigaki, H. Tajima, A. Nakabayashi, Y. Yoshimura and Y. Hosoim, Green tea extracts attenuate doxorubicin-induced spermatogenic disorders in conjunction with higher telomerase activity in mice, J. Assist. Reprod. Genet. 27 (2010) 501-508; DOI: 10.1007/s10815-010- -9438-z.Search in Google Scholar

21. N. Kassner, K. Huse, H. J. Martin, U. Gödtel-Armbrust, A. Metzger, I. Meineke, J. Brockmöller, K. Klein, U. M. Zanger, E. Maser and L. Wojnowski, Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver, Drug Metab. Dispos. 36 (2008) 2113-2120; DOI: 10.1124/dmd.108.022251.10.1124/dmd.108.02225118635746Search in Google Scholar

22. W. X. Huang, L. Y. Ding, Q. A. Huang, H. Hu, S. Liu, X. Yang, X. Hu, Y. Dang, S. Shen, J. Li, X. Ji, S. Jiang, J. O. Liu and L. Yu, Carbonyl reductase 1 as a novel target of (-)-epigallocatechin gallate against hepatocellular carcinoma, Hepatology 52 (2010) 703-714; DOI: 10.1002/hep.23723.10.1002/hep.2372320683966Search in Google Scholar

23. M. N. Berry, A. Edwards and G. Barritt, Isolated Hepatocytes: Preparation, Properties and Applications, Elsevier Science Publishers, Amsterdam 1991, pp. 15-58.Search in Google Scholar

24. H. Wang and J. A. Joseph, Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader, Free Rad. Biol. Med. 27 (1999) 612-616; DOI: 10.1016/s0891-5849(99) 00107-0.Search in Google Scholar

25. N. P. Seeram, Y. J. Zhang and M. G. Nair, Inhibition of proliferation of human cancer cells and cyclooxygenase enzymes by anthocyanidins and catechins, Nutr. Cancer 46 (2003) 101-106; DOI: 10.1207/s15327914nc4601_13.10.1207/S15327914NC4601_1312925310Search in Google Scholar

26. G. Liang, A. Z. Tang, X. Z. Lin, L. Li, S. Zhang, Z. Huang, H. Tang and Q. Q. Li, Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer, Int. J. Oncol. 37 (2010) 111-123; DOI: 10.3892/ijo_00000659.10.3892/ijo_00000659Search in Google Scholar

27. G. W. Dryden, A. Lam, K. Beatty, H. H. Qazzaz and C. J. McClain, A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis, Inflamm. Bowel Dis. 19 (2013) 1904-1912; DOI: 10.1097/MIB.0b013e31828f5198.10.1097/MIB.0b013e31828f519823846486Search in Google Scholar

28. H. H. Chow, I. A. Hakim, D. R. Vining, J. A. Crowell, J. Ranger-Moore, W. M. Chew, C. A. Celaya, S. R. Rodney, Y. Hara and D. S. Alberts, Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals, Clin. Cancer Res. 11 (2005) 4627-4633; DOI: 10.1158/1078-0432.CCR-04-2549.10.1158/1078-0432.CCR-04-254915958649Search in Google Scholar

29. G. Stammler and M. Volm, Green tea catechins (EGCG and EGC) have modulating effects on the activity of doxorubicin in drug-resistant cell lines, Anti-cancer Drugs 8 (1997) 265-268.10.1097/00001813-199703000-000079095331Search in Google Scholar

30. G. Mazzanti, F. Menniti-Ippolito, P. A. Moro, F. Cassetti, R. Raschetti, C. Santuccio and S. Mastrangelo, Hepatotoxicity from green tea: a review of the literature and two unpublished cases, Eur. J. Clin. Pharmacol. 65 (2009) 331-341; DOI: 10.1007/s00228-008-0610-7 10.1007/s00228-008-0610-719198822Search in Google Scholar